Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCVAC/OvCa added to first-line carboplatin-paclitaxel for newly diagnosed epithelial ovarian carcinoma
2013-001322-26Phase 2Completed
- Sponsor
- SOTIO Biotech
- Start
- Jul 2013
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of DCvac in epithelial ovarian cancer (EOC) (3 arms), sponsored by SOTIO Biotech. Started Jul 2013; status: completed.
02
Drugs
DCvac
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2013-001322-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001322-26.